Search

Your search keyword '"Yuthavisuthi P"' showing total 2 results
Start Over Author "Yuthavisuthi P" Database Supplemental Index
2 results on '"Yuthavisuthi P"'

1. Tenofovir Versus Placebo to Prevent Perinatal Transmission of Hepatitis B

Author

Jourdain, Gonzague, Ngo-Giang-Huong, Nicole, Harrison, Linda, Decker, Luc, Khamduang, Woottichai, Tierney, Camlin, Salvadori, Nicolas, Cressey, Tim R., Sirirungsi, Wasna, Achalapong, Jullapong, Yuthavisuthi, Prapap, Kanjanavikai, Prateep, Na Ayudhaya, Orada P., Siriwachirachai, Thitiporn, Prommas, Sinart, Sabsanong, Prapan, Limtrakul, Aram, Varadisai, Supang, Putiyanun, Chaiwat, Suriyachai, Pornnapa, Liampongsabuddhi, Prateung, Sangsawang, Suraphan, Matanasarawut, Wanmanee, Buranabanjasatean, Sudanee, Puernngooluerm, Pichit, Bowonwatanuwong, Chureeratana, Puthanakit, Thanyawee, Klinbuayaem, Virat, Thongsawat, Satawat, Thanprasertsuk, Sombat, Siberry, George K., Watts, Diane H., Chakhtoura, Nahida, Murphy, Trudy V., Nelson, Noele P., Chung, Raymond T., Pol, Stanislas, and Chotivanich, Nantasak

Abstract

(Abstracted from N Engl J Med2018;378:911–923)(Pregnant women with an elevated viral load (>200,000 IU/mL) of hepatitis B virus (HBV), or with a positive Hg e antigen (HBeAg) status, have a risk of transmitting infection to their infants, despite the infants' receiving hepatitis B immune globulin (HBIG). Antiviral agents that inhibit HBV replication, such as lamivudine, tenofovir disoproxil fumarate (TDF), and telbivudine, when administered to pregnant women with a high HBV viral load, may reduce the risk of mother-to-child transmission.

Published
2018
Full Text
View/download PDF

2. Early Postpartum Pharmacokinetics of Lopinavir Initiated Intrapartum in Thai Women

Author

Cressey, Tim R., Van Dyke, Russell, Jourdain, Gonzague, Puthanakit, Thanyawee, Roongpisuthipong, Anuvat, Achalapong, Jullapong, Yuthavisuthi, Prapap, Prommas, Sinart, Chotivanich, Nantasak, Maupin, Robert, Smith, Elizabeth, Shapiro, David E., and Mirochnick, Mark

Abstract

ABSTRACTLopinavir (LPV) exposure is reduced during the third trimester of pregnancy. We report the pharmacokinetics of standard LPV-ritonavir dosing (400/100 mg twice daily) in the immediate and early postpartum period when initiated during labor. In 16 human immunodeficiency virus-infected Thai women, the median (range) LPV area under the concentration-time curve and maximum and minimum concentrations in plasma were 99.7 (66.1 to 180.5) μg·h/ml, 11.2 (8.0 to 17.5) μg/ml, and 4.6 (1.7 to 12.5) μg/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results